These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36181471)

  • 21. Prader-Willi Syndrome: Possibilities of Weight Gain Prevention and Treatment.
    Erhardt É; Molnár D
    Nutrients; 2022 May; 14(9):. PubMed ID: 35565916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful early dietary intervention avoids obesity in patients with Prader-Willi syndrome: a ten-year follow-up.
    Schmidt H; Pozza SB; Bonfig W; Schwarz HP; Dokoupil K
    J Pediatr Endocrinol Metab; 2008 Jul; 21(7):651-5. PubMed ID: 18780599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin.
    Damen L; Grootjen LN; Juriaans AF; Donze SH; Huisman TM; Visser JA; Delhanty PJD; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2021 May; 94(5):774-785. PubMed ID: 33296519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
    Kimonis V; Surampalli A; Wencel M; Gold JA; Cowen NM
    PLoS One; 2019; 14(9):e0221615. PubMed ID: 31545799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the causes of obesity in children with trisomy 21: hyperphagia vs physical inactivity.
    Foerste T; Sabin M; Reid S; Reddihough D
    J Intellect Disabil Res; 2016 Sep; 60(9):856-64. PubMed ID: 26936540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
    Cadena-Obando DA; Molina-Ayala MA; Ferreira-Hermosillo A
    Nutr Hosp; 2018 May; 35(3):743-746. PubMed ID: 29974787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.
    Tan Q; Orsso CE; Deehan EC; Triador L; Field CJ; Tun HM; Han JC; Müller TD; Haqq AM
    Obes Rev; 2020 May; 21(5):e12992. PubMed ID: 31889409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.
    Bensignor MO; Bramante CT; Bomberg EM; Fox CK; Hale PM; Kelly AS; Mamadi R; Prabhu N; Harder-Lauridsen NM; Gross AC
    Pediatr Obes; 2023 Sep; 18(9):e13061. PubMed ID: 37264767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome.
    Miller JL; Lacroix A; Bird LM; Shoemaker AH; Haqq A; Deal CL; Clark KA; Ames MH; Suico JG; de la Peña A; Fortier C
    J Clin Endocrinol Metab; 2022 May; 107(6):e2373-e2380. PubMed ID: 35213714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific Dietary Components and Gut Microbiota Composition are Associated with Obesity in Children and Adolescents with Prader-Willi Syndrome.
    Garcia-Ribera S; Amat-Bou M; Climent E; Llobet M; Chenoll E; Corripio R; Ibáñez L; Ramon-Krauel M; Lerin C
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32290434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.
    Goldman VE; Naguib MN; Vidmar AP
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment.
    Höybye C; Barkeling B; Espelund U; Petersson M; Thorén M
    Growth Horm IGF Res; 2003 Dec; 13(6):322-7. PubMed ID: 14624765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The modified Atkins diet in children with Prader-Willi syndrome.
    Felix G; Kossoff E; Barron B; Krekel C; Testa EG; Scheimann A
    Orphanet J Rare Dis; 2020 Jun; 15(1):135. PubMed ID: 32493369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Avenues for Pharmacological Management of Hyperphagia and Associated Behavioral Disorders in Prader-Willi Syndrome.
    Castellano JM; Ariza-Jimenez AB; Tena-Sempere M
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e895-e896. PubMed ID: 36896885
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
    Miller JL; Linville TD; Dykens EM
    J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):23-9. PubMed ID: 23893676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of obesity in Prader-Willi syndrome.
    Khan MJ; Gerasimidis K; Edwards CA; Shaikh MG
    Pediatr Obes; 2018 Jan; 13(1):3-13. PubMed ID: 27863129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of a transdisciplinary approach on hyperphagia management among patients with Prader Willi syndrome.
    Pedemonti B; Ceccomancini R; D'Acunti A; Stegmann J
    Endocrinol Diabetes Nutr (Engl Ed); 2023 May; 70(5):347-351. PubMed ID: 37263734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study.
    Miller JL; Tamura R; Butler MG; Kimonis V; Sulsona C; Gold JA; Driscoll DJ
    Am J Med Genet A; 2017 May; 173(5):1243-1250. PubMed ID: 28371242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
    Mastrandrea LD; Witten L; Carlsson Petri KC; Hale PM; Hedman HK; Riesenberg RA
    Pediatr Obes; 2019 May; 14(5):e12495. PubMed ID: 30653847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.